Organization | ikfe GmbH

ikfe GmbH Report issue

For profit Phase 2 Phase 4

Founded: Mainz Germany (2008)

Organization Overview

First Clinical Trial

2008

NCT00941148

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Alternative names

ikfe-CRO GmbH | Ikfe GmbH | ikfe GmbH, Institut for Klinische Forschung und Entwicklung, Parcusstr. 8, 55116 Mainz, Germany | Marcus Borchert

Active Ingredients

Drugs in Phase 4 Trials (11)

glimepiride (amaryl) (2 trials)

insulin detemir (Levemir) (1 trial)

insulin glargine (toujeo) (2 trials)

insulin glulisine (Apidra) (2 trials)

insulin human (humulin) (3 trials)

insulin lispro (humalog) (1 trial)

linagliptin (tradjenta) (2 trials)

liraglutide (victoza) (1 trial)

saxagliptin (onglyza) (1 trial)

sitagliptin (januvia) (3 trials)

vildagliptin (1 trial)

Drugs in Phase 2 Trials (1)

cebranopadol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Albuminuria (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Neuropathies (Phase 2)

Hypertension (Phase 3)

Polyneuropathies (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 12